SOD1 and type 2 diabetes mellitus: Another study by Shigiyama et al. named DEFENCE trial showed that the dapagliflozin add-on to metformin had improvement in oxidative stress by a significant reduction in the levels of urinary oxidative biomarker 8-hydroxy-2′-deoxyguanosin [16]. A study by Nabrdalik-Leśniak et al. demonstrated that SGLT2i treatment affects the urine antioxidant status by improvement of the SOD antioxidant activity in T2DM patients, which could be the mechanism behind its nephroprotective activity [17].